CrossrefInfokarteTirofiban vs standard antiplatelet therapy in acute branch atheromatous disease-related stroke: a multicenter, randomized, open-label, blinded-endpoint, parallel-group, phase III clinical trial
Shengde Li, Haizhou Hu, Dingding Zhang, Bin Liu, Mengfei Zhong, Lihua Wang, Qingsong Yang, Ping Zhang, Weili Zhao, Fengli Zhao, Yufeng Tang, Xiaoli Wang, Heng Li, Liwei Chen, Guofang Chen, Rui Wang, Aiqin Dong, Zhidong Zheng, Xiaona Wang, Qin Liu, Jiangtao Zhang, Jiacai Wang, Li Wang, Xin Li, Hong Chen, Junfang Ma, Yuhua Zhao, Yuhui Sha, Thanh Nguyen, Duolao Wang, Lixin Zhou, Yicheng Zhu, Bin Peng, Jun Ni, Jun Ni, Lixin Zhou, Ming Yao, Shengde Li, Haizhou Hu, Yuhui Sha
The Lancet Regional Health - Western Pacific · 2026-10 · 75 · 101995
DOI: 10.1016/j.lanwpc.2026.101995 ↗